Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 2647-2652

  Hoggatt, Jonathan ^a   Tate, Tiffany A ^a   Pelus, Louis M ^b  

^a Harvard University   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biosimilar; Cancer; Filgrastim; Granulocyte colony stimulating factor; Neutrophil; XM22

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; DOXORUBICIN; FILGRASTIM; GRANULOCYTE COLONY STIMULATING FACTOR; LIPEGFILGRASTIM; PEGFILGRASTIM; PLACEBO; RECOMBINANT PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ALOPECIA; ANOREXIA; ASTHENIA; BONE PAIN; BREAST CANCER; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CONTINUOUS INFUSION; DIARRHEA; DISEASE SEVERITY; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MARKETING; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; FATIGUE; FEBRILE NEUTROPENIA; HEADACHE; HEALTH CARE COST; HUMAN; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; REVIEW; SINGLE DRUG DOSE; VOMITING; CHEMISTRY; CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA;

CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; RECOMBINANT PROTEINS;

EID: 84928152583     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S55796     Document Type: Review

References (36)

1. Hirsch J. An anniversary for cancer chemotherapy. JAMA. 2006;296(12):1518-1520.
2. Goodman LS, Wintrobe MM. Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. JAMA. 1946;132:126-132.
3. Ogawa M. Differentiation and proliferation of hematopoietic stem cells. Blood. 1993;81(11):2844-2853.
4. Summers C, Rankin SM, Condliffe AM, Singh N, Peters AM, Chilvers ER. Neutrophil kinetics in health and disease. Trends Immunol. 2010;31(8):318-324.
5. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004;100(2):228-237.
6. National Cancer Institute Common Terminology Criteria for Adverse Advents v3.0 (CTCAE) [Internet]; 2015. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf. Accessed August 9, 2006.
7. Nesher L, Rolston KV. The current spectrum of infection in cancer patients with chemotherapy related neutropenia. Infection. 2014;42(1):5-13.
8. Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer. 2005;103(9):1916-1924.
9. Michels SL, Barron RL, Reynolds MW, Smoyer Tomic K, Yu J, Lyman GH. Costs associated with febrile neutropenia in the US. Pharmacoeconomics. 2012;30(9):809-823.
10. Schilling MB, Parks C, Deeter RG. Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: a retrospective study. Exp Ther Med. 2011;2(5):859-866.
11. Nagata S, Tsuchiya M, Asano S, et al. The chromosomal gene structure and two mRNAs for human granulocyte colony-stimulating factor. EMBO J. 1986;5(3):575-581.
12. Platzer E, Oez S, Welte K, et al. Human pluripotent hemopoietic colony stimulating factor: activities on human and murine cells. Immunobiology. 1986;172(3-5):185-193.
13. Souza LM, Boone TC, Gabrilove J, et al. Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science. 1986;232(4746):61-65.
14. Welte K, Platzer E, Lu L, et al. Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor. Proc Natl Acad Sci U S A. 1985;82(5):1526-1530.
15. Dührsen U, Villeval JL, Boyd J, Kannourakis G, Morstyn G, Metcalf D. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood. 1988;72(6):2074-2081.
16. Welte K, Bonilla MA, Gillio AP, et al. Recombinant human granulocyte colony-stimulating factor. Effects on hematopoiesis in normal and cyclophosphamide-treated primates. J Exp Med. 1987;165(4):941-948.
17. Ikebuchi K, Ihle JN, Hirai Y, Wong GG, Clark SC, Ogawa M. Synergistic factors for stem cell proliferation: further studies of the target stem cells and the mechanism of stimulation by interleukin-1, interleukin-6, and granulocyte colony-stimulating factor. Blood. 1988;72(6):2007-2014.
18. Ikebuchi K, Clark SC, Ihle JN, Souza LM, Ogawa M. Granulocyte colony-stimulating factor enhances interleukin 3-dependent proliferation of multipotential hemopoietic progenitors. Proc Natl Acad Sci U S A. 1988;85(10):3445-3449.
19. Metcalf D, Nicola NA. Proliferative effects of purified granulocyte colony-stimulating factor (G-CSF) on normal mouse hemopoietic cells. J Cell Physiol. 1983;116(2):198-206.
20. Bronchud MH, Scarffe JH, Thatcher N, et al. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer. 1987;56(6):809-813.
21. Gabrilove JL, Jakubowski A, Scher H, et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med. 1988;318(22):1414-1422.
22. Gabrilove JL, Jakubowski A, Fain K, et al. Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium. J Clin Invest. 1988;82(4):1454-1461.
23. Morstyn G, Campbell L, Souza LM, et al. Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet. 1988;1(8587):667-672.
24. Lord BI, Woolford LB, Molineux G. Kinetics of neutrophil production in normal and neutropenic animals during the response to filgrastim (r-metHu G-CSF) or filgrastim SD/01 (PEG-r-metHu G-CSF). Clin Cancer Res. 2001;7(7):2085-2090.
25. Johnston E, Crawford J, Blackwell S, et al. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol. 2000;18(13):2522-2528.
26. Green MD, Koelbl H, Baselga J, et al; International Pegfilgrastim 749 Study Group. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2003;14(1):29-35.
27. Hoggatt J, Pelus LM. New G-CSF agonists for neutropenia therapy. Expert Opin Investig Drugs. 2014;23(1):21-35.
28. Abdolzade-Bavil A, Cooksey B, Scheckermann C, et al. Pegylated versus glycopegylated G-CSFs and their biochemical and physiological properties [abstract]. Blood. 2013;122:4851.
29. Mahlert F, Schmidt K, Allgaier H, Liu P, Müller U, David Shen W. Rational development of lipegfilgrastim, a novel long-acting granulocyte colony-stimulating factor, using glycopegylation technology [abstract]. Blood. 2013;122:4853.
30. European Medicines Agency Product Information: Lonquex [Internet]; 2015. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002556/WC500148380.pdf
31. Buchner A, Lammerich A, Abdolzade-Bavil A, Muller U, Bias P. Lipegfilgrastim: pharmacodynamics and pharmacokinetics for body-weight-adjusted and 6 mg fixed doses in two randomized studies in healthy volunteers. Curr Med Res Opin. 2014;30(12):2523-2533.
32. Armstrong JK, Hempel G, Koling S, et al. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer. 2007;110(1):103-111.
33. Richter AW, Akerblom E. Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors. Int Arch Allergy Appl Immunol. 1984;74(1):36-39.
34. Bondarenko I, Gladkov OA, Elsaesser R, Buchner A, Bias P. Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy. BMC Cancer. 2013;13:386.
35. Buchner A, Elsasser R, Bias P. A randomized, double-blind, active control, multicenter, dose-finding study of lipegfilgrastim (XM22) in breast cancer patients receiving myelosuppressive therapy. Breast Cancer Res Treat. 2014;148(1):107-116.
36. Volovat C, Bondarenko IM, Gladkov OA, et al. Efficacy and safety of lipegfilgrastim in elderly patients with non-small-cell lung cancer receiving cisplatin/etoposide chemotherapy. J Geraitr Oncol. 2012;3(Sup 1):S97-S98.